This multicenter, double-blind, randomized, parallel-group fixed-dose study of 8 weeks' duration was performed to define the maximum tolerated dose of nateglinide in a prediabetic population.
Nateglinide was very well tolerated. The overall incidence of AEs, other than symptoms of hypoglycemia, was low and similar among all treatment groups. No deaths occurred during the study ...